Spun out of research conducted at the University of Wisconsin Madison, SHINE Medical Technologies Inc manufactures and supplies medical tracers and cancer treatment elements and is working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented proprietary manufacturing process offering major advantages over existing and proposed production technologies: does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nationâs existing supply chain for moly-99. The company offers Molybdenum-99, a light-emitting element that is administered to patients for the purpose of diagnosing and staging cancer and heart diseases. To an extent, the firm is focused on developent of cost-effective and greener production methods to address US shortage of molybdenum-99 medical isotope. SHINE Medical also provides Iodine-131 that is used to treat thyroid cancer and various abnormal thyroid conditions, including hyper-thyroidism, as well as to diagnose liver function, renal blood flow, and urinary tract obstruction; and Iodine-125 that is used in the treatment of prostate cancer and brain tumors, as well as to evaluate kidney function and diagnose deep vein thrombosis in the leg; and Xenon-133 that is inhaled as a gas to evaluate regional function in emphysema and various forms of chronic and obstructive lung diseases
